MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Price, Quote, News and Overview
TSX:MDNA - Toronto Stock Exchange - CA58490H1073 - Common Stock - Currency: CAD
MDNA.CA Quote, Performance and Key Statistics
TSX:MDNA (5/22/2025, 7:00:00 PM)
1.1
-0.05 (-4.35%)
The current stock price of MDNA.CA is 1.1 CAD. In the past month the price increased by 5.77%. In the past year, price decreased by -53.39%.
MDNA.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 307.74M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 236.65M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 184.99M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 165.53M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 15.94 | 74.31M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 69.24M | ||
| BLU.CA | BLUENERGIES LTD | N/A | 57.06M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 55.07M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 50.90M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | 34 | 47.95M | ||
| ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 44.41M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 32.00M |
Related stock screener links
About MDNA.CA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 16 full-time employees. The company went IPO on 2015-07-13. The firm's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
MEDICENNA THERAPEUTICS CORP
2 Bloor St W., 7Th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Gino L. DeMichele
Employees: 16
Phone: 14166485555
MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ
What is the stock price of MEDICENNA THERAPEUTICS CORP today?
The current stock price of MDNA.CA is 1.1 CAD. The price decreased by -4.35% in the last trading session.
What is the ticker symbol for MEDICENNA THERAPEUTICS CORP stock?
The exchange symbol of MEDICENNA THERAPEUTICS CORP is MDNA and it is listed on the Toronto Stock Exchange exchange.
On which exchange is MDNA.CA stock listed?
MDNA.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for MEDICENNA THERAPEUTICS CORP stock?
10 analysts have analysed MDNA.CA and the average price target is 4.09 CAD. This implies a price increase of 271.76% is expected in the next year compared to the current price of 1.1. Check the MEDICENNA THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEDICENNA THERAPEUTICS CORP worth?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a market capitalization of 86.04M CAD. This makes MDNA.CA a Micro Cap stock.
How many employees does MEDICENNA THERAPEUTICS CORP have?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) currently has 16 employees.
What are the support and resistance levels for MEDICENNA THERAPEUTICS CORP (MDNA.CA) stock?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a support level at 1 and a resistance level at 1.13. Check the full technical report for a detailed analysis of MDNA.CA support and resistance levels.
Should I buy MEDICENNA THERAPEUTICS CORP (MDNA.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDNA.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDNA.CA, evaluating the profitability, health, valuation and growth aspects
- MEDICENNA THERAPEUTICS CORP (MDNA.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEDICENNA THERAPEUTICS CORP (MDNA.CA) Sales and EPS estimates to see what analysts future expectations are.
- MEDICENNA THERAPEUTICS CORP (MDNA.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEDICENNA THERAPEUTICS CORP (MDNA.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Chart to make your own analysis
- MEDICENNA THERAPEUTICS CORP (MDNA.CA) Latest news and press-releases to stay up to date.
Does MEDICENNA THERAPEUTICS CORP (MDNA.CA) stock pay dividends?
MDNA.CA does not pay a dividend.
When does MEDICENNA THERAPEUTICS CORP (MDNA.CA) report earnings?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) will report earnings on 2025-06-25, after the market close.
What is the Price/Earnings (PE) ratio of MEDICENNA THERAPEUTICS CORP (MDNA.CA)?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
MDNA.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MDNA.CA. When comparing the yearly performance of all stocks, MDNA.CA is a bad performer in the overall market: 87.92% of all stocks are doing better.
MDNA.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDNA.CA. While MDNA.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
MDNA.CA Financial Highlights
Over the last trailing twelve months MDNA.CA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -68.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.43% | ||
| ROE | -154.12% | ||
| Debt/Equity | 0.01 |
MDNA.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to MDNA.CA. The Buy consensus is the average rating of analysts ratings from 10 analysts.